CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory Study,Journal of Neuroimmune Pharmacology

当前位置： X-MOL 学术 › J. Neuroimmune Pharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory Study
Journal of Neuroimmune Pharmacology ( IF 6.2 ) Pub Date : 2023-03-16 , DOI: 10.1007/s11481-023-10058-x
Martin K R Svačina ₁ , Anika Meißner ₁ , Finja Schweitzer ₁ , Alina Sprenger-Svačina ₁ , Ines Klein ₁ , Hauke Wüstenberg ₁ , Felix Kohle ₁ , Helene L Walter ₁ , Michael Schroeter ₁ , Helmar C Lehmann _{1,

2}

Affiliation

Availability of COVID-19 mRNA vaccine for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg) raises the question of whether COVID-19 mRNA vaccine influences disease activity or IVIg-mediated immunomodulation in CIDP. In this exploratory study, blood samples of CIDP patients on IVIg treatment were longitudinally analyzed before and after vaccination with a COVID-19 mRNA vaccine. A total of 44 samples of eleven patients were characterized at four timepoints by ELISA and flow cytometry in terms of immunomarkers for disease activity and IVIg-immunomodulation. Apart from a significantly lower expression of CD32b on naïve B cells after vaccination, no significant alteration of immunomarkers for CIDP or IVIg-mediated immunomodulation was observed. Our exploratory study suggests that COVID-19 mRNA vaccine does not have a relevant impact on immune activity in CIDP. In addition, immunomodulatory effects of IVIg in CIDP are not altered by COVID-19 mRNA vaccine. This study was registered in the German clinical trial register (DRKS00025759).

Graphical Abstract

Overview over the study design. Blood samples of CIDP patients on recurrent IVIg treatment and vaccination with a COVID-19 mRNA vaccine were obtained at four timepoints for cytokine ELISA and flow cytometry, to assess key cytokines and cellular immunomarkers for disease activity and IVIg-immunomodulation in CIDP.

中文翻译：

CIDP：COVID-19 mRNA 疫苗接种和 IVIg 免疫调节期间免疫标志物分析：一项探索性研究

对于接受静脉注射免疫球蛋白 (IVIg) 治疗的慢性炎症性脱髓鞘性多发性神经病 (CIDP) 患者来说，使用 COVID-19 mRNA 疫苗引发了一个问题：COVID-19 mRNA 疫苗是否会影响 CIDP 的疾病活动性或 IVIg 介导的免疫调节。在这项探索性研究中，对接受 IVIg 治疗的 CIDP 患者在接种 COVID-19 mRNA 疫苗之前和之后的血液样本进行了纵向分析。通过 ELISA 和流式细胞术在四个时间点对 11 名患者的总共 44 个样本进行了疾病活动和 IVIg 免疫调节的免疫标记物的表征。除了接种疫苗后幼稚 B 细胞上 CD32b 的表达显着降低外，没有观察到 CIDP 或 IVIg 介导的免疫调节的免疫标记物发生显着变化。我们的探索性研究表明，COVID-19 mRNA 疫苗对 CIDP 的免疫活性没有相关影响。此外，CIDP 中 IVIg 的免疫调节作用不会因 COVID-19 mRNA 疫苗而改变。该研究已在德国临床试验注册中心注册（DRKS00025759）。